Perkinelmer Inc. is aiming to boost its infectious disease testing footprint with the acquisition of Oxford Immunotec Global plc for $591 million in cash. The purchase, reported Thursday, will allow Perkinelmer to expand its current offerings with solutions for tuberculosis (TB) detection. Perkinelmer shares (NYSE:PKI) hit a high of $162.16 Thursday morning, before closing at $160.53 – up 2.66% from the Wednesday’s close of $156.37.
Pixium Vision SA and Second Sight Medical Products Inc. have inked a definitive agreement through which the former will become the controlling shareholder of the newly combined company. The transaction also will result in the creation of a new entity that will focus on cortical stimulation through Orion. Second Sight is developing that product, which bypasses the diseased eye and could provide a new form of vision.
Flowonix Medical Inc. and Swk Holdings Corp. closed a $33 million financing that included $10 million in debt facility from Swk in addition to $23 million in a series B round led by returning investor Farallon Capital Management with support from several new investors. The financing will replace approximately $7.5 million in prior venture debt from Hercules Capital. It will also fund development of new products, entry into new disease markets, production expansion, and partnerships with pharmaceutical companies.
HONG KONG – Votis Subdermal Imaging Technologies Ltd. is developing a diagnostics solution that could prevent the loss of feet among India’s impoverished due to affects of peripheral artery disease (PAD). The company has entered an agreement with India’s Ii Ventures Pte. Ltd. (iiV) to develop a system to screen the largely rural Indian population for PAD.
Hologic Inc., which focuses on women’s health, said Jan. 4 that it has completed the acquisition of Somatex Medical Technologies GmbH for roughly $64 million. Based in Berlin, Somatex focuses on minimally invasive devices for tumor diagnostics, biopsy and interventional specialties. Somatex’s portfolio includes biopsy site markers and localization technologies, including Trumark markers. The company was previously owned by E-Med Solutions GmbH, a group of investors led by German private equity firm Westlake Partners.
PARIS – Solvay SA is partnering with Printerprezz Inc. to develop 3D printing technology using Selective Laser Sintering (SLS) for implants and other medical devices.
Bayer Corp. and Veracyte Inc. are collaborating in the thyroid cancer space, with an eye toward identifying underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. South San Francisco-based Veracyte offers the Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA), which aims to help physicians in terms of thyroid cancer diagnosis and individualized care.
PARIS – Tilak Healthcare SAS is signing an ophthalmology partnership agreement with Novartis AG from Basel, Switzerland, to expand international distribution of its vision monitoring technology, Odysight.
Royal Philips NV is expanding its cardio footprint with the acquisition of Biotelemetry Inc., a manufacturer of remote medical technologies, for $2.8 billion, or $72 per share. The proposed deal, announced Friday, furthers Philips’ goal of providing integrated solutions across the care continuum, with Biotelemetry’s cardiac diagnostics and monitoring tools joining Philips’ line of hospital-based patient monitoring solutions. Philips expects the Biotelemetry business to contribute to sales growth and EBITA margin in 2021 and deliver double-digit growth and improve profit margins to more than 20% by 2025.
Alphatec Holdings Inc. has renewed a commitment to buy Eos Imaging SA, saying it will now pick up the company for $79.7 million, plus the retirement of $37.2 million in debt, in an all-cash deal. Both company’s boards have approved the execution of a tender offer agreement, through which Carlsbad, Calif.-based Alphatec will launch a cash tender offer for all the issued and outstanding shares and convertible notes of Eos imaging for a total purchase price of $116.9 million.